Epstein-Barr virus latent membrane protein 1 peptide–Major Histocompatibility Complex Class I complex (LMP1-pMHC-I)

The LMP1-derived peptide–MHC-I complex is a critical immunological target formed when fragments of the Epstein-Barr virus (EBV) Latent Membrane Protein 1 (LMP1) are processed and presented on the cell surface by Major Histocompatibility Complex Class I molecules. LMP1 is a well-characterized viral oncogene that mimics CD40 signaling to promote cell survival and proliferation, and it is expressed in various EBV-associated malignancies such as nasopharyngeal carcinoma and Hodgkin lymphoma (UniProt P03230). Because LMP1 is an intracellular or transmembrane protein with limited extracellular exposure, the peptide-MHC complex (pMHC) serves as a vital 'window' for the immune system to identify infected or transformed cells. Therapeutic strategies targeting this complex include T-cell receptor-engineered T cells (TCR-T) and TCR-like antibodies, which are designed to recognize specific peptide sequences, such as the HLA-A*02:01-restricted YLQQNWWTL epitope (PubMed: 28235901). These therapies aim to bypass the immune evasion tactics of EBV-positive tumors by providing high-affinity recognition of viral antigens. Monitoring HLA status and LMP1 expression is essential for patient selection in clinical trials utilizing these modalities.

Other names

LMP1-HLA-A*02:01 complexEBV LMP1 peptide-MHC complexLMP1-derived peptide-HLA complexYLQQNWWTL-HLA-A2 complex

Targeting of the peptide-MHC complex by T-cell receptors (TCRs) or TCR-like antibodies to induce direct T-cell mediated lysis of EBV-infected tumor cells, cytokine release, and recruitment of the adaptive immune system.